| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447880 | European Journal of Cancer | 2010 | 6 Pages |
Abstract
Raised LDH is associated with a poor prognosis in recurrent GCTs and outperforms established prognostic models in this setting. LDH as a prognostic factor should be validated prospectively and should also be assessed in patients receiving conventional dose chemotherapy regimens.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marco Gerlinger, Peter Wilson, Thomas Powles, Jonathan Shamash,